S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
LYEL · Lyell Immunopharma, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Lyell Immunopharma Inc (LYEL)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$9.41
-0.30
(-3.09%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$9.41
$9.32
$9.79
52-WEEK RANGE
$9.41
$7.20
$45.00
What's happening
- LYEL is down 3.09% today, trading at $9.41. — Live quote
- Volume today (7,040) is well below its 3-month average of 178,480. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.92 actual vs. $-2.06 estimated (+6.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 8
Hold 1
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LYEL
-68.49%
vs S&P 500
-81.26%
1-YEAR RETURN
LYEL
-46.23%
vs S&P 500
-60.79%
6-MONTH RETURN
LYEL
-59.07%
3-MONTH RETURN
LYEL
-26.01%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.92
Est. $-2.06
BEAT +6.7%
2026-04-26 (Q1 2026)
$-1.10
Est. $-2.41
BEAT +54.4%
2026-01-26 (Q4 2025)
$-7.50
Est. $-2.28
MISS -229.5%
2025-10-26 (Q3 2025)
$-2.13
Est. $-2.70
BEAT +21.0%
Valuation Measures & Ratios
Enterprise Value4$164.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)8803.70
Price / Book71.40
EV4 / Revenue6100.55
EV4 / EBITDA—
Profit Margin-920285.19%
Operating Margin-949981.48%
Return on Equity (ROE8)-91.62%
Return on Assets (ROA9)-70.50%
Avg Volume (3M)178,480
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $328.0M | $441.6M | $275.8M | $131.4M | $158.8M |
| P/E | -2.18 | -2.80 | -1.55 | -0.71 | -0.78 |
| Price/Sales | 11309.32 | 13798.77 | 4310.05 | 2118.95 | 2785.91 |
| Price/Book | 1.40 | 1.61 | 0.84 | 0.44 | 0.47 |
| EV/Revenue | 8792.59 | 10962.21 | 2379.19 | 525.34 | 674.89 |
| EV/EBITDA | -1.54 | -2.01 | -0.85 | — | — |
| ROE | -64.34% | -57.69% | -54.18% | -61.98% | -60.40% |
| ROA | -48.35% | -45.03% | -43.71% | -48.07% | -47.29% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,263,394
Change from Prior Settlement+6.36%
% of Float—
Days to Cover (Short Ratio)7.40
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -50.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -920285.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -46.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LYEL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0K | $2.0K | $15.0K | $8.0K | $7.0K | $34.0K | $13.0K | $3.0K |
| Operating income | -$47.3M | -$44.3M | -$37.3M | -$47.1M | -$57.4M | -$50.5M | -$51.5M | -$55.6M |
| Net income | -$44.8M | -$24.2M | -$38.8M | -$42.7M | -$52.2M | -$44.6M | -$45.8M | -$60.7M |
| EPS (diluted) | $-1.92 | $-1.10 | $-2.13 | $-2.89 | $-3.54 | $-3.48 | $-3.59 | $-0.24 |
| EPS (basic) | $-1.92 | $-1.10 | $-2.13 | $-2.89 | $-3.54 | $-3.48 | $-3.59 | $-0.24 |
| Operating margin | -$1.2M | -$2.2M | -$248.4K | -$589.2K | -$819.5K | -$148.5K | -$396.4K | -$1.9M |
| Net margin | -$1.1M | -$1.2M | -$259.0K | -$533.5K | -$745.6K | -$131.1K | -$352.4K | -$2.0M |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $311.2M | $350.6M | $340.1M | $408.0M | $385.5M | $429.8M | $490.9M | $619.2M |
| Total liabilities | $77.3M | $77.0M | $91.8M | $78.8M | $86.5M | $93.3M | $108.0M | $88.5M |
| Stockholders' equity | $233.8M | $273.7M | $248.2M | $329.1M | $298.9M | $336.5M | $382.8M | $530.7M |
| Total current assets | $213.5M | $267.3M | $260.9M | $328.2M | $282.2M | $309.2M | $379.6M | $450.0M |
| Total current liabilities | $39.9M | $36.9M | $49.4M | $31.9M | $36.9M | $41.3M | $53.8M | $33.5M |
| Cash & equivalents | $73.0M | $90.8M | $60.2M | $123.6M | $98.8M | $120.3M | $105.6M | $100.3M |
| Marketable securities (current) | $131.1M | $163.3M | $187.0M | $196.0M | $178.0M | $180.8M | $264.9M | $340.2M |
| Marketable securities (non-current) | $23.9M | $7.0M | $0 | $0 | $20.1M | $28.9M | $13.0M | $20.1M |
| Property, plant & equipment | $30.5M | $32.7M | $34.8M | $36.7M | $39.1M | $44.2M | $48.2M | $88.0M |
| Other non-current assets | $5.8M | $5.2M | $4.9M | $2.5M | $2.5M | $3.2M | $4.6M | $5.1M |
| Accounts payable | $3.9M | $5.5M | $2.9M | $2.6M | $3.4M | $3.7M | $5.4M | $3.6M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $537.0K | $527.0K | $517.0K | $2.7M | $3.0M | $3.1M | $3.3M | $3.6M |
| Common stock & paid-in capital | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $30.0K | $1.0K | $26.0K |
| Retained earnings | -$1.69B | -$1.64B | -$1.62B | -$1.48B | -$1.44B | -$1.40B | -$1.35B | -$1.15B |
| Accumulated other comprehensive income (loss) | -$158.0K | -$9.0K | $242.0K | $201.0K | $57.0K | $158.0K | $291.0K | $760.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.9M | -$38.5M | -$32.3M | -$28.6M | -$34.5M | -$54.7M | -$47.2M | -$35.0M |
| Investing cash flow | $15.6M | $17.4M | -$31.4M | $3.3M | $12.6M | $69.5M | $53.5M | $1.9M |
| Financing cash flow | $522.0K | $51.7M | $222.0K | $50.0M | $183.0K | $1.0K | $437.0K | $0 |
| Free cash flow | -$34.2M | -$38.6M | -$32.6M | -$28.6M | -$34.6M | -$55.0M | -$47.3M | -$35.1M |
| Capital expenditures | $256.0K | $89.0K | $304.0K | $62.0K | $168.0K | $246.0K | $44.0K | $59.0K |
| Depreciation & amortization | $2.2M | $2.3M | $2.4M | $2.6M | $3.1M | $3.4M | $5.0M | $4.7M |
| Share-based compensation | $4.5M | $4.3M | $25.6M | $5.2M | $5.0M | $6.0M | $8.1M | $7.6M |
| Change in accounts payable | -$1.5M | $2.4M | $325.0K | -$779.0K | -$231.0K | -$1.7M | -$2.0M | -$568.0K |
| Purchases of investments | $53.5M | $37.2M | $42.8M | $71.0M | $80.7M | $84.4M | $38.8M | $131.4M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | $0 | $1.0K | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.7M | $10.7M |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M |
| EPS (diluted) | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 |
| EPS (basic) | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 |
| Operating margin | -$748.3K | -$588.1K | -$190.0K | -$221 | -$2.0K |
| Net margin | -$762.4K | -$562.3K | -$180.5K | -$216 | -$2.3K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.13B |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M |
| Stockholders' equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M |
| Total current assets | $260.9M | $379.6M | $554.7M | $651.3M | $626.3M |
| Total current liabilities | $49.4M | $53.8M | $34.5M | $37.0M | $46.7M |
| Cash & equivalents | $60.2M | $105.6M | $145.6M | $123.6M | $293.8M |
| Marketable securities (current) | $187.0M | $264.9M | $400.6M | $516.6M | $321.0M |
| Marketable securities (non-current) | $0 | $13.0M | $16.5M | $70.1M | $283.5M |
| Property, plant & equipment | $34.8M | $48.2M | $102.7M | $123.0M | $120.1M |
| Other non-current assets | $4.9M | $4.6M | $4.2M | $4.7M | $3.5M |
| Accounts payable | $2.9M | $5.4M | $4.8M | $3.9M | $3.2M |
| Deferred revenue (current) | — | — | — | $0 | $5.0M |
| Other non-current liabilities | $517.0K | $3.3M | $3.7M | $4.1M | $4.6M |
| Common stock & paid-in capital | $2.0K | $1.0K | $25.0K | $25.0K | $24.0K |
| Retained earnings | -$1.62B | -$1.35B | -$1.00B | -$767.5M | -$584.4M |
| Accumulated other comprehensive income (loss) | $242.0K | $291.0K | -$94.0K | -$7.6M | -$1.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M |
| Investing cash flow | $54.1M | $122.4M | $184.0M | -$11.5M | -$121.6M |
| Financing cash flow | $50.4M | $1.3M | $1.7M | $10.6M | $401.2M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M | -$191.8M |
| Capital expenditures | $780.0K | $464.0K | $2.7M | $24.3M | $65.5M |
| Depreciation & amortization | $11.5M | $19.6M | $20.2M | $18.0M | $13.6M |
| Share-based compensation | $41.8M | $33.1M | $47.1M | $81.9M | $62.2M |
| Change in accounts payable | -$2.3M | -$3.2M | $1.5M | $667.0K | $91.0K |
| Purchases of investments | $278.9M | $394.7M | $476.9M | $406.3M | $673.5M |
| Share repurchases | — | — | — | $0 | $0 |
| Tax withholding on stock comp | $1.0K | $76.0K | $457.0K | $461.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LYEL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-11 to 2026-10-12
Recent transactions
- Insiders have net sold 15,032 shares over the last 182 days, across 0 purchases and 15 sales.
- Most recent: Aguirre Jarrad Mattieu (Chief Medical Officer) — Open market sale of 422 shares on 2026-10-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)15,032 sh(15 txns)
Net Shares-15,032
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Aguirre Jarrad Mattieu | Chief Medical Officer | Open market sale | 2026-10-12 | 422 |
| Shook David | Chief Medical Officer | Open market sale | 2026-09-10 | 500 |
| Seely Lynn | President and CEO | Open market sale | 2026-08-21 | 9,589 |
| Hill Stephen J. | Chief Operating Officer | Open market sale | 2026-08-21 | 989 |
| Lee Gary K. | Chief Scientific Officer | Open market sale | 2026-08-21 | 1,457 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | 2026-08-10 | 621 |
| Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Other acquisition/disposition | 2026-07-27 | 44,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-12 | Aguirre Jarrad Mattieu | Chief Medical Officer | Open market sale | 422 | $8.63 |
| 2026-09-10 | Shook David | Chief Medical Officer | Open market sale | 500 | $12.70 |
| 2026-08-21 | Seely Lynn | President and CEO | Open market sale | 9,589 | $15.54 |
| 2026-08-21 | Hill Stephen J. | Chief Operating Officer | Open market sale | 989 | $15.54 |
| 2026-08-21 | Lee Gary K. | Chief Scientific Officer | Open market sale | 1,457 | $15.54 |
| 2026-08-10 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | 621 | $14.34 |
| 2026-08-10 | Lee Gary K. | Chief Scientific Officer | Open market sale | 131 | $14.34 |
| 2026-08-10 | Hill Stephen J. | Chief Operating Officer | Open market sale | 89 | $14.34 |
| 2026-08-10 | Seely Lynn | President and CEO | Open market sale | 390 | $14.34 |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Other acquisition/disposition | 44,000 | $0.00 |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Other acquisition/disposition | 38,500 | $0.00 |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Open market sale | 10 | $13.70 |
| 2026-07-16 | Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Open market sale | 10 | $13.73 |
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Other acquisition/disposition | 76,000 | $0.00 |
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd | Reporting person | Other acquisition/disposition | 66,500 | $0.00 |
| 2026-05-11 | Seely Lynn | President and CEO | Open market sale | 388 | $18.91 |
| 2026-05-11 | Lee Gary K. | Chief Scientific Officer | Open market sale | 130 | $18.92 |
| 2026-05-11 | Hill Stephen J. | Chief Operating Officer | Open market sale | 89 | $18.92 |
| 2026-05-11 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | 217 | $18.91 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:17 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-10 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about LYEL (Lyell Immunopharma, Inc.). Links open the publisher — we don’t host full articles.
-
We're Keeping An Eye On Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Rate
Simply Wall Street · 2026-10-21 -
The Technical Signals Behind (LYEL) That Institutions Follow
Stock Traders Daily · 2026-10-18 -
LYEL Oct 2026 12.000 put (LYEL261016P00012000) interactive stock chart
Yahoo Finance UK · 2026-10-17 -
Lyell Immunopharma CMO sells 422 shares: USD 40.86 target for Lyell Immunopharma stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-16 -
LYEL Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.5% - Basic EPS Analysis
https://www.siam.in/ · 2026-10-16 -
LYEL Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.5% - Profit Margin Analysis
https://www.dars.gov.et/ · 2026-10-16 -
Lyell Immunopharma (LYEL) Climbs 6.39% to $7.99 as Buyers Press Toward Resistance - Triple Top
https://www.siam.in/ · 2026-10-15 -
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Yahoo · 2026-10-13
No headlines in this category right now — try “All”.